Gaucher's Disease Global Market Report 2024

The gaucher’s disease market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.68 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be ascribed to the development of enzyme replacement therapy (ERT), heightened awareness of the disease, advancements in genetic research and diagnosis, initiatives in patient advocacy, and government incentives targeting rare diseases.

The gaucher’s disease market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period can be linked to the emergence of next-generation therapies, the expansion of global patient registries, enhanced access to treatment, personalized medicine strategies, and regulatory backing for rare diseases. Key trends projected in the forecast period encompass technological advancements in treatment monitoring, international research collaborations, progress in oral therapeutics, the expansion of newborn screening programs, and global initiatives fostering patient access.

The gaucher's disease market is anticipated to experience growth due to the increasing prevalence of genetic abnormalities. Genetic abnormalities involve mutations in a person's DNA sequence, leading to abnormal features or functions. Gaucher's disease, with an autosomal recessive inheritance pattern, requires individuals to inherit two mutated GBA gene copies to develop the condition. Those affected by Gaucher's disease lack sufficient enzyme production, resulting in lipid buildup in organs such as the spleen and liver. Notably, reports from MedlinePlus in May 2021 highlighted the identification of syndrome A in about 1 in 200,000 Americans annually, with around 100,000 children suffering from syndrome B. Additionally, an estimated 12,000 global deaths occurred from syndrome C in 2020, and approximately 1% of individuals in the United States developed disorder D during their lifetimes. This increasing prevalence of genetic abnormalities is a driving factor in the growth of the Gaucher's disease market.

The growth of the Gaucher's disease market is expected to be fueled by the rising number of clinical trials. Clinical trials, involving human participants, evaluate the safety and efficacy of new medical treatments, interventions, or drugs. Increased clinical trials in Gaucher's disease can lead to advancements in treatment, better disease understanding, improved diagnosis and screening, and the potential development of personalized medicine. According to Xtalks in May 2023, there are 452,604 registered clinical studies, with 64,838 actively seeking participants. This marks a substantial increase from the 365,000 registered trials in 2021, contributing significantly to the growth of the Gaucher's disease market.

Challenges to the growth of the Gaucher's disease market are anticipated due to the lack of imiglucerase supply. Imiglucerase is a crucial medication for Gaucher disease, replacing the deficient enzyme. The scarcity of imiglucerase, as reported by the National Library of Medicine in August 2022, resulted in adverse clinical effects for Italian patients with Gaucher type I. This shortage poses a hindrance to the growth of the Gaucher disease market.

Major companies in the Gaucher's disease market are adopting innovative technologies such as next-generation sequencing (NGS) to enhance patient care. NGS, a high-throughput sequencing technology, enables rapid and cost-effective DNA and RNA sequencing. For instance, Eurofins Genomics LLC launched a whole plasmid sequencing service utilizing advanced Gen3 NGS technology, offering same-day results with up to 99% single-base accuracy. This service, accommodating DNA constructs from 2.5 to 300 kb, combines the accuracy and quick turnaround of Sanger sequencing with NGS's comprehensive analysis capabilities, providing a cost-effective and time-efficient solution for genetic analysis.

In January 2021, Eli Lilly and Company, a US-based pharmaceutical company, acquired Prevail Therapeutics Inc. for $1.04 billion. This acquisition aims to expand Lilly's drug discovery and development approach, launching a gene therapy program supported by Prevail's clinical-stage and preclinical neuroscience assets. Prevail Therapeutics Inc., a gene therapy company, focuses on developing treatments for various Gaucher disease types, including neuronopathic Gaucher disease and Type 1 Gaucher disease.

Major companies operating in the gaucher’s disease market report are Pfizer Inc., Johnson & Johnson, Merck and Co. Inc., Novartis AG, Sanofi S.A., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Moderna Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, BioMarin Pharmaceutical Inc., CHIESI Farmaceutici SPA, IntraBio Inc., REGENXBIO Inc., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Pharming Group N.V., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, AVROBIO Inc., Resverlogix Corp., GenSight Biologics S.A., ISU Abxis Co. Ltd., SIRION BIOTECH GmbH, Greenovation Biotech GmbH, Orphazyme A/S.

North America was the largest region in the Gaucher's disease market in 2023. Europe is expected to be the fastest growing region in the forecast period. The regions covered in the gaucher’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the gaucher’s disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gaucher's disease market includes revenues earned by entities by providing services such as genetic counseling, patient education and support, research and clinical trials, and pain management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The gaucher's disease market consists of sales of bone health supplements, medical equipment, and diagnostic testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary categories of Gaucher’s disease encompass Gaucher disease type 1, Gaucher disease type 2, Gaucher disease type 3, and others. Gaucher disease type 1, the most prevalent form, is distinguished by a deficiency of the enzyme glucocerebrosidase. The diverse diagnostic methods include physical examinations, blood tests, imaging tests, preconception screening, prenatal testing, and others. Treatment options involve enzyme replacement therapy and substrate reduction therapy, which can be administered through oral, parenteral, and various other routes by end users such as hospitals, specialty clinics, homecare, and others.

The Gaucher’s disease market research report is one of a series of new reports that provides Gaucher’s disease market statistics, including the Gaucher’s disease industry global market size, regional shares, competitors with Gaucher’s disease market share, detailed Gaucher’s disease market segments, market trends and opportunities, and any further data you may need to thrive in the Gaucher’s disease industry. This Gaucher’s disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.